Stephenson Harwood LLP acted as the Hong Kong legal adviser to Lansen Pharmaceutical Holdings Limited (Lansen Pharmaceutical) on its privatisation by Cathay International Pharma Manufacture And Distribution (China) Limited, involving a total consideration of approximately HK$240 million.
Lansen Pharmaceutical is an investment holding company incorporated in the Cayman Islands. Together with its subsidiaries, it is primarily dedicated to the research, development, production and sale of pharmaceuticals relating to the fields of rheumatology, dermatology, medical cosmetology and plant extraction.
A corporate team from the Hong Kong office advised in each stage of the privatisation by way of a scheme of arrangement under section 86 of the Cayman Islands Companies Act and Lansen Pharmaceutical's subsequent delisting from the Hong Kong Stock Exchange.
This transaction demonstrates Stephenson Harwood's capability in providing practical solutions in the arenas of privatisation and delisting. Additionally, the team was not only able to ensure client compliance with the Listing Rules, the Securities and Futures Ordinance, and the Takeovers Code, but also to navigate the Hong Kong regulatory landscape, providing comprehensive guidance to safeguard client interests.
The team was led by Hong Kong corporate partner Michelle Chung, who was supported by associate Alexis Fang.
